Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a CRISPR genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies / N, Keane; Natoni, Alessandro; M, Sharik; M, Chesi; Pl, Bergsagel; M, O'Dwyer. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 103:Supplement 1(2018), pp. 9-10.
Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a CRISPR genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies
Alessandro NatoniInvestigation
;
2018
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
